TNF and inflammatory bowel disease: Cost benefits are a key driver of anti-TNF-α biosimilar uptake: in a 2023 global survey of 234 physicians with expertise in IBD, 54.7% of physicians familiar with infliximab and adalimumab biosimilars listed their lower cost as the main reason behind physician decision to use biosimilars in clinical practice [50].